Evolution of menopausal hormone therapy: from standard to ultra-low doses

Abstract

The article tells about the incidence and severity of menopausal symptoms in women during pre-, peri- and post-menopausal periods as well as the rationale for their treatment. It was found that the use of menopausal hormone therapy (MHT) should be individualized and should not be cancelled solely due to the woman's age. The results of numerous studies of women in the transition from pre- to peri- and further to postmenopause are demonstrated. Limitations in the duration of MHT therapy are considered, and the need to develop safer therapies for long-term treatment of hot flushes is substantiated. It is proved that ultra-low-dose medication is effective for the treatment of both moderate and severe vasomotor symptoms.

Keywords

• менопаузальные симптомы
• мгт
• длительность лечения мгт
• вазомоторные симптомы
• низко- и ультранизкодозированные системные
• эстрогены
• menopausal symptoms
• mht
• duration of mht treatment
• vasomotor symptoms
• low and ultra-low-dose low systemic estrogens